DeuteRx Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

DeuteRx General Information

Description

Operator of a virtual biopharmaceutical company intended to improve racemic drugs for patients. The company develops new chemical entities that are preferred, stabilized enantiomers of known racemic drugs that are currently a mixture of two interconverting enantiomers, enabling clients to advance small molecule therapies through Deuterium-Enriched Chiral Switching.

Contact Information

Website
www.deuterx.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 300 Brickstone Square
  • Suite 201
  • Andover, MA 01810
  • United States
+1 (978)
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 300 Brickstone Square
  • Suite 201
  • Andover, MA 01810
  • United States
+1 (978)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DeuteRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Oct-2023 Completed Pre-Clinical Trials
2. Angel (individual) Cancelled Pre-Clinical Trials
1. Seed Round 30-Sep-2015 $2.8M $2.8M Completed Startup
To view DeuteRx’s complete valuation and funding history, request access »

DeuteRx Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • Pending

  • Expiring in next 12 mo

DeuteRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120302605-A1 3-deutero-pomalidomide Inactive 18-Nov-2010
CA-2818361-A1 3'-deutero-pomalidomide Inactive 18-Nov-2010
AU-2011329619-A1 3-deutero-pomalidomide Inactive 18-Nov-2010
US-20130274291-A1 3'-deutero-pomalidomide Inactive 18-Nov-2010
EP-2640189-A1 3-deutero-pomalidomide Inactive 18-Nov-2010 C07D401/04
To view DeuteRx’s complete patent history, request access »

DeuteRx Executive Team (3)

Name Title Board Seat
Sheila DeWitt Ph.D Chief Executive Officer, President & Chairman
Kimberlee Drapkin Financial Advisor
You’re viewing 2 of 3 executive team members. Get the full list »

DeuteRx Board Members (3)

Name Representing Role Since
Leonardus Van der Ploeg Ph.D Self Board Member and Strategy and R&D Advisor
Michael Webb Self Board Member & Business Advisor
Sheila DeWitt Ph.D DeuteRx Chief Executive Officer, President & Chairman
To view DeuteRx’s complete board members history, request access »

DeuteRx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

DeuteRx FAQs

  • When was DeuteRx founded?

    DeuteRx was founded in 2012.

  • Who is the founder of DeuteRx?

    Anthony Czarnik Ph.D is the founder of DeuteRx.

  • Who is the CEO of DeuteRx?

    Sheila DeWitt Ph.D is the CEO of DeuteRx.

  • Where is DeuteRx headquartered?

    DeuteRx is headquartered in Andover, MA.

  • What is the size of DeuteRx?

    DeuteRx has 5 total employees.

  • What industry is DeuteRx in?

    DeuteRx’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is DeuteRx a private or public company?

    DeuteRx is a Private company.

  • What is DeuteRx’s current revenue?

    The current revenue for DeuteRx is .

  • How much funding has DeuteRx raised over time?

    DeuteRx has raised $2.8M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »